Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

Fig. 6

Subset of the IMVigor 210 study (n = 274) classified according to the latest consensus molecular subtype classification, separated by a Mutational status regarding RB1 and TP53 alterations and b binary response to atezolizumab: Responders (CR + PR) and Non-responders (SD + PD)). The y-axis in this figure refers to the number of patients

Back to article page